Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.

European journal of cancer (Oxford, England : 1990) - 1 Mar 2008

Patel Shreyaskumar, Zalcberg John R

Abstract excerpt

Imatinib therapy for unresectable or metastatic gastrointestinal stromal tumour (GIST) is typically initiated at a dosage of 400mg/d. Two phase 3 studies investigated whether the higher dose of 800 mg/d - administered initially or upon progression on the 400-mg dose - would improve outcomes. Both the studies confirmed the 400mg/d starting dose for most patients. However, two groups benefited from the treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Multicenter Studies as Topic

Share to Piperazines

Share to Randomized Controlled Trials as Topic

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Identifiers

PMID: 18234488
DOI: 10.1016/j.ejca.2007.11.021

Genes

KIT
BID

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.PMID 18234488Read ↗

The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.Semantic proximity Read ↗

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.Semantic proximity Read ↗

Optimal use of targeted agents for advanced gastrointestinal stromal tumours.Semantic proximity Read ↗

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.Semantic proximity Read ↗

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.Semantic proximity Read ↗

Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.Semantic proximity Read ↗

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.Semantic proximity Read ↗

Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.Semantic proximity Read ↗

Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.Semantic proximity Read ↗

Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.